vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and HANMI FINANCIAL CORP (HAFC). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $37.2M, roughly 1.9× GYRE THERAPEUTICS, INC.). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -3.7%, a 33.5% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 10.4%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
GYRE vs HAFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $71.2M |
| Net Profit | $-1.4M | $21.2M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 29.8% |
| Net Margin | -3.7% | 29.8% |
| Revenue YoY | 33.4% | 17.1% |
| Net Profit YoY | -340.1% | 20.0% |
| EPS (diluted) | $-0.01 | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $71.2M | ||
| Q3 25 | $30.6M | $71.0M | ||
| Q2 25 | $26.8M | $65.2M | ||
| Q1 25 | $22.1M | $62.8M | ||
| Q4 24 | $27.9M | $60.8M | ||
| Q3 24 | $25.5M | $58.5M | ||
| Q2 24 | $25.2M | $56.7M | ||
| Q1 24 | $27.2M | $58.4M |
| Q4 25 | $-1.4M | $21.2M | ||
| Q3 25 | $5.9M | $22.1M | ||
| Q2 25 | $1.6M | $15.1M | ||
| Q1 25 | $3.7M | $17.7M | ||
| Q4 24 | $569.0K | $17.7M | ||
| Q3 24 | $2.9M | $14.9M | ||
| Q2 24 | $4.5M | $14.5M | ||
| Q1 24 | $9.9M | $15.2M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 29.8% | ||
| Q3 25 | 22.7% | 31.1% | ||
| Q2 25 | 8.1% | 23.2% | ||
| Q1 25 | 10.3% | 28.1% | ||
| Q4 24 | 2.4% | 29.1% | ||
| Q3 24 | 16.6% | 25.5% | ||
| Q2 24 | 12.7% | 25.5% | ||
| Q1 24 | 29.7% | 26.0% |
| Q4 25 | -3.7% | 29.8% | ||
| Q3 25 | 19.4% | 31.1% | ||
| Q2 25 | 5.9% | 23.2% | ||
| Q1 25 | 16.9% | 28.1% | ||
| Q4 24 | 2.0% | 29.1% | ||
| Q3 24 | 11.2% | 25.5% | ||
| Q2 24 | 18.0% | 25.5% | ||
| Q1 24 | 36.6% | 26.0% |
| Q4 25 | $-0.01 | $0.70 | ||
| Q3 25 | $0.03 | $0.73 | ||
| Q2 25 | $0.00 | $0.50 | ||
| Q1 25 | $0.00 | $0.58 | ||
| Q4 24 | $0.00 | $0.58 | ||
| Q3 24 | $0.01 | $0.49 | ||
| Q2 24 | $0.01 | $0.48 | ||
| Q1 24 | $0.03 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $796.4M |
| Total Assets | $166.1M | $7.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $37.4M | — |
| Q4 25 | $106.0M | $796.4M | ||
| Q3 25 | $101.9M | $779.5M | ||
| Q2 25 | $92.0M | $762.8M | ||
| Q1 25 | $68.1M | $751.5M | ||
| Q4 24 | $63.3M | $732.2M | ||
| Q3 24 | $63.2M | $736.7M | ||
| Q2 24 | $60.4M | $707.1M | ||
| Q1 24 | $56.6M | $703.1M |
| Q4 25 | $166.1M | $7.9B | ||
| Q3 25 | $159.4M | $7.9B | ||
| Q2 25 | $152.6M | $7.9B | ||
| Q1 25 | $129.8M | $7.7B | ||
| Q4 24 | $125.4M | $7.7B | ||
| Q3 24 | $125.2M | $7.7B | ||
| Q2 24 | $120.9M | $7.6B | ||
| Q1 24 | $122.0M | $7.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $206.0M |
| Free Cash FlowOCF − Capex | $-5.8M | $203.7M |
| FCF MarginFCF / Revenue | -15.5% | 286.2% |
| Capex IntensityCapex / Revenue | 0.4% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 9.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $356.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $206.0M | ||
| Q3 25 | $4.7M | $146.9M | ||
| Q2 25 | $2.1M | $-19.0M | ||
| Q1 25 | $-129.0K | $25.8M | ||
| Q4 24 | $-2.8M | $52.6M | ||
| Q3 24 | $1.7M | $6.7M | ||
| Q2 24 | $-5.5M | $2.1M | ||
| Q1 24 | $2.9M | $30.0M |
| Q4 25 | $-5.8M | $203.7M | ||
| Q3 25 | $4.0M | $146.4M | ||
| Q2 25 | $1.8M | $-19.6M | ||
| Q1 25 | $-251.0K | $25.6M | ||
| Q4 24 | $-2.8M | $49.9M | ||
| Q3 24 | $1.0M | $6.5M | ||
| Q2 24 | $-6.9M | $1.3M | ||
| Q1 24 | $2.7M | $29.2M |
| Q4 25 | -15.5% | 286.2% | ||
| Q3 25 | 13.1% | 206.3% | ||
| Q2 25 | 6.8% | -30.0% | ||
| Q1 25 | -1.1% | 40.7% | ||
| Q4 24 | -10.1% | 82.1% | ||
| Q3 24 | 4.1% | 11.1% | ||
| Q2 24 | -27.5% | 2.3% | ||
| Q1 24 | 9.8% | 50.0% |
| Q4 25 | 0.4% | 3.2% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.0% | 0.9% | ||
| Q1 25 | 0.6% | 0.4% | ||
| Q4 24 | 0.2% | 4.3% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 5.8% | 1.4% | ||
| Q1 24 | 0.9% | 1.4% |
| Q4 25 | — | 9.70× | ||
| Q3 25 | 0.79× | 6.66× | ||
| Q2 25 | 1.32× | -1.26× | ||
| Q1 25 | -0.03× | 1.46× | ||
| Q4 24 | -4.85× | 2.97× | ||
| Q3 24 | 0.60× | 0.45× | ||
| Q2 24 | -1.21× | 0.14× | ||
| Q1 24 | 0.29× | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
